PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “IBDV”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 55 records · Page 3Linked to original sources

[Cloning, expression and preparation of polyclonal antibody for IBDV non-structure protein gene].

Infectious bursal disease virus (IBDV) VP5 gene was amplified and cloned into an N-terminal GST-Tag fusion expression vector, pGEX-4T-2, which was controlled by T7 promoter. The sequencing result showed that the VP5 gene was composed of 438 base pairs, and coded 145 amino acids. High VP5 product was expressed in E. coli BL21 induced by IPTG, and the GST-VP5 fusion protein existed in inclusion. High titer anti-VP5 serum was also prepared in New Zealand rabbit immunized with purified fusion protein inclusion. These results gave a basis for further research for VP5 function in IBDV replication and pathogenicity, which also paved the way for developing VP5 gene deleted IBDV live vaccine.

Animals↗

Coding region of segment A sequence of a very virulent isolate of IBDV--comparison with isolates from different countries and virulence.

We determined the sequence of the coding region of segment A, coding for the viral proteins (VPs) VP2, VP4, and VP3, of a very virulent (vv) infectious bursal disease virus (IBDV) isolated in Israel and named IBDVks. We compared the deduced amino acid sequences of the proteins of the new isolate with those of the same proteins from several IBDV isolates, as published in recent years. The amino acid sequences of VP3 and VP4 of the Israeli isolate were 1.9%-2.3% different from the sequences of their counterparts from classical strains. Thus, the stable region of VP2 of IBDVks was very similar (0-0.68% difference) to the same region of VP2 from vv strains from Europe and Japan but distinct from that of proteins from classical strains from Europe, the United States, and Australia (up to 9.42% divergence), showing that IBDVks is more closely related to the vv strains from Europe and Japan. We found that viruses isolated in recent years resemble each other more than isolates from the same areas isolated a few years earlier. Hence, IBDVks can be categorized in one group with vv new isolates from Europe and Japan. This group has been found to be distinct from new isolates in the United States and strains isolated before the IBDV epidemic during the late 1980s.

Animals↗

Pathogenic and structural properties of wild type infectious bursal disease virus (IBDV) and virus grown in vitro.

Large plaque (LP) and small plaque (SP) variants of Infectious Bursal Disease Virus (IBDV) which are formed in vitro after serial passages in CE-cells at low or high multiplicities of infection were tested for their pathogenic properties in susceptible chickens. LP virus caused clinical manifestations and destruction of the Bursa of Fabricius (BF) without killing the animals. No signs of a disease appeared after infection with SP virus, and only limited necrotic foci developed in the BF. Coinfection with the SP variant and the highly pathogenic wild type (wt) virus reduced mortality and the severity of the disease. In contrast to the SP variant, which forms incomplete particles of low density, with one or the other of the two genomic RNA segments missing, the two RNA segments characteristic for IBDV were present in approximately equal amounts in wt particles with a buoyant density of 1.29 g/ml isolated from the BF. In spite of an almost total replacement of one of the two major structural polypeptides with a molecular weight of 32 kd by a 28 kd protein, infectivity in this low density fraction was only slightly reduced. This finding underlines the importance of the type of post-translational modification in lymphoid cells or fibroblasts.

Animals↗

Purification of capsid-like particles of infectious bursal disease virus (IBDV) VP2 expressed in E. coli with a metal-ion affinity membrane system.

Protein VP2, matured from the polyprotein encoded by the genome of infectious bursal disease virus (IBDV) and the primary host-protective immunogen of this virus, together with its two N-terminal truncated mutants were cloned and expressed in Escherichia coli. To obtain pure recombinant proteins for the development of an efficient subunit vaccine against IBDV infection, these three proteins were fused with six additional histidine residues at their C-termini as a His-purification-tag. Following purification employing immobilized metal-ion (Ni2+) affinity chromatography (IMAC), a purification fold of approximately 104 was achieved. Electron microscopic observation also demonstrated that all three E. coli-derived proteins form the morphology of icosahedral particles of approximately 25 nm in diameter. To reduce the cost of resin used for IMAC, self-prepared immobilized metal-ion affinity membranes (IMAM), i.e., commercial, regenerated cellulose membrane modified with iminodiacetic acid and immobilized with nickel ions, was applied to purify particles formed by these three proteins. A 104-fold of purification efficiency was also achieved by this membrane, showing that under the same conditions the recovery and purification efficiency of IMAM are comparable with those of IMAC. The pure VP2-formed particles thus obtained, coupled with their uniform dimensions, not only facilitate a better understanding of the structural biology of these immunogenic particles but also help the development of improved vaccines against this avian virus.

Cellulose↗

Examination of the value of treatment of decompensated viral hepatitis patients by intentionally coinfecting them with an apathogenic IBDV and using the lessons learnt to seriously consider treating patients infected with HIV using the apathogenic hepatitis G virus.

Hepatitis virus infection persistent worldwide (approximately 600 m people) results in chronic hepatitis progressing to hepatocellular carcinoma (HCC) in many (approximately 1 m deaths/year). The review examines the usefulness of treating chronic viral hepatitis, including decompensated patients, by intentional coinfection with an attenuated infectious bursal disease virus (IBDV; apathogenic in man, stable at pH 2, orally administered). Learning lessons from the IBDV studies, the case is made to treat human immunodeficiency virus (HIV) infected patients (worldwide prevalence approximately 50 m people) by coinfecting with apathogenic hepatitis G virus (GBV-C). These ideas are reinforced by (i) eight out of ten studies reporting a beneficial effect of GBV-C viremia on HIV-related mortality or response to therapy and (ii) the recent reports of improved or delayed survival of HIV patients, naturally coinfected with an apathogenic virus.

GB virus C↗

Ultrastructural studies on interaction of infectious bursal disease virus (IBDV) and aflatoxin B1 on chick embryo fibroblast cell culture.

Light and electron microscopic evaluation of chick embryo fibroblast (CEF) cell culture inoculated with graded doses (0.25, 2.5 and 25 micrograms/ml medium) of aflatoxin B1 with and without infectious bursal disease virus (IBDV) was undertaken. The light microscopy revealed degeneration, detachment and necrosis of fibroblasts and multiple plaques formation in IBDV infected group without and with (0.25, 2.5 micrograms) aflatoxin B1. The cultures infected with virus, with or without 25 micrograms aflatoxin B1 showed complete detachment from glass surface. Electron microscopy of these cultures showed marked pyknotic or bizarre shaped nuclei, pronounced degenerative changes in the rough endoplasmic reticulum (RER), mitochondria and the presence of multiple vacuoles in the cytoplasm. The viruses were spherical, arrayed, complete, generally closer to nuclei and RER and indistinctly membrane bound. The viruses were either localised or scattered in the cytoplasm. Cultures containing 25 micrograms aflatoxin B1 without or infected with virus showed marked necrosis of cells. In latter group only a few viruses were seen either in infected cells or free in culture. Control cultures failed to show cytopathic changes as observed in the other three groups.

Aflatoxin B1↗

Preparation of ChIL-2 and IBDV VP2 fusion protein by baculovirus expression system.

This study aims to produce an effective subunit vaccine against infectious bursal disease virus (IBDV). The genes of chicken interleukin-2 (ChIL-2) and IBDV viral protein 2 (VP2) were amplified and fused by splice overlap extension-polymerase chain reaction (SOE-PCR). The fusion gene was digested by EcoR I/Kpn I and inserted into pBacPAK8 vector, resulting in recombinant transfer plasmid pBacPakVP2-IL2. The recombinant plasmid was transfected into Sf-9 cells accompanied with hybrid nuclear polyhedrosis virus (HyNPV) genome DNA and lipofectin. Plaque-purification indicated that we had got the recombinant Hy-VP2-IL2. Fusion protein VP2-IL2 was expressed effectively both in insect cells and bombyx mori. The expression of fusion protein was confirmed by ELISA, SDS-PAGE and Western blotting assay, respectively. This efficient system allows us to meet the need for inexpensive vaccines required by the poultry industry.

Animals↗

Mapping of cross-reacting and serotype-specific epitopes on the VP3 structural protein of the infectious bursal disease virus (IBDV).

The binding sites of a panel of monoclonal antibodies cross-reacting with the structural protein VP3 of the two serotypes of the infectious bursal disease virus (IBDV) could be mapped to four segments of the VP3 gene. Two of these antigenic domains also carry epitopes which are specific for one serotype only. Formation of the common or type-specific epitopes is in agreement with homologous or mismatching amino acid sequences yielding hydrophilic segments on the VP3 polypeptide. These antigenic patterns obtained by immunoblotting could be verified by a competitive ELISA.

Animals↗

Infiltration by CD4+ and CD8+ lymphocytes in bursa of chickens infected with Infectious Bursal Disease Virus (IBDV): strain-specific differences.

In order to investigate if there is any definite correlation between the degree of T-cell response in the bursa of Fabricius (BF) and the virulence of Infectious Bursal Disease (IBD) virus strains, chickens were infected with strains of different virulence i.e. mild (Lukert strain), intermediate (Georgia strain) or invasive intermediate (IV-95 strain). At various times post-inoculation, bursal samples were collected to study virus specific histopathological lesions, the distribution of viral antigen and the extent of T-cell infiltration in the bursa. Most severe bursal lesions were induced by IV-95 strain (the invasive intermediate strain), whereas Lukert, the mild strain caused the least severe lesions. The number of virus positive cells in the bursa was highest in chickens infected with IV-95 strain. Substantial infiltration of CD4+ and CD8+ T-cells in the bursal follicles of virus-infected groups was observed from 4 d.p.i. onwards. The magnitude of T-cell response was more in the birds infected with intermediate (Georgia) or invasive intermediate strains of virus than chickens inoculated with mild (Lukert) strain, even when 10-fold higher doses of the inoculums were used. PHA responses to peripheral lymphocytes were found suppressed in all the groups of chickens only transiently. The results indicate that the magnitude of T-cell responses in BF during IBDV infection is influenced more by the virulence of virus strain rather than the quantum of viral load in BF. Over all these studies may have implications in understanding the role of T-cells in pathogenesis and immunity in IBD.

Animals↗

Genetic and phenotypic correlations between antibody responses to Escherichia coli, infectious bursa disease virus (IBDV), and Newcastle disease virus (NDV), in broiler lines selected on antibody response to Escherichia coli.

The genetic control of antibody (Ab) response to Escherichia coli (EC), infectious bursa disease virus, and Newcastle disease virus and the genetic and phenotypic correlation between these Ab responses, were evaluated under farm conditions in which chicks were simultaneously exposed to these antigens. The experimental population comprised five groups: two lines divergently selected for high (HH) or low (LL) Ab response to EC vaccination; a commercial broiler dam-line (CC), from which HH and LL had been derived; and the HH x CC and LL x CC hybrid groups (HC and LC, respectively). Lines LL and HH expressed similar symmetric divergence to all three antigens. The ranking of the LL, LC, CC, HC, and HH genetic groups according to their mean Ab responses and their very high linear correlation with the LL vs. HH genomic scale clearly indicate the additive nature of the genetic divergence between these lines. Several estimates of correlation were calculated between Ab responses of each pair of antigens and between BW and Ab to each antigen. The high correlation between group means, the near-zero within-group correlation, and the low phenotypic correlation indicate the strongly positive genetic correlation between Ab responses and no correlation with BW. The results of this study suggest that overall immunocompetence of commercial broilers can be improved by selection for high Ab response of young chicks to controlled immunization with a single antigen, without counteracting further selection for high BW.

Animals↗

Virus enhancement following infection with antibody-coated infectious bursal disease virus (IBDV) in chickens.

A novel concept of vaccination, employing virus-antibody complex has been reported for the control of infectious bursal disease in chickens. A comparison of virus replication, serum neutralizing antibody response and pathogenicity in chickens inoculated with the antibody coated virus, prepared by mixing virus and antibody in different ratios (1:1, 1:0.1, 1: 0.01) and virus alone without antibody, has been made. Antibody coated virus (when mixed in certain crucial ratios) replicated to a higher magnitude in the target organ, caused more severe pathogenesis but induced a primary serum neutralizing antibody response almost comparable. The results may have important implications in understanding of pathogenesis and development of control strategies against infectious bursal disease virus, specially employing immune complex vaccine.

Animals↗

Antigenic characterization of IBDV field isolates by their reactivity with a panel of monoclonal antibodies.

Recently Infectious Bursal Disease Virus isolates have been described in USA displaying an antigenic drift. Many of the new isolates were very virulent for chickens. In several European countries severe outbreaks of Gumboro disease have also been reported from vaccinated and non-vaccinated flocks. Since vaccinated SPF birds were shown to be protected against challenge infection with the new isolates under laboratory conditions, a more detailed investigation of the European isolates is wanted. The similarity between the European and US field situation got us to use a panel of monoclonal antibodies (MCAs) previously applied to characterize US strains for testing European isolates. An antigen capture ELISA has been carried out directly on bursa homogenates of chickens form the field. One European (F52/70) and two US (Var. E and GLS-5) strains have been included as reference viruses. From the results presented here it can be concluded that the European isolates (Netherlands, France, UK, Germany, Jugoslavia and Spain) did not undergo the same antigenic drift as the US strains. A more extensive analysis of the isolates will be done to elucidate their role for disease outbreaks.

Animals↗

Comparative immunopathogenesis of mild, intermediate, and virulent strains of classic infectious bursal disease virus.

Differences in the immunopathogenesis of several strains of infectious bursal disease virus (IBDV) were compared. The strains included a virulent virus (IBDV-IM) and three vaccine viruses that included an intermediate vaccine virus (IBDV-B2) and two mild vaccine viruses (IBDV-Lukert and IBDV-BVM). The most significant differences were found in the systemic effects of these strains. In comparison with other strains, IBDV-IM antigen was detectable for up to 8 days postinfection (PI) in lymphoid tissues that included spleen and cecal tonsils, whereas only a few IBDV-B2- and IBDV-Lukert- and no IBDV-BVM-inoculated birds had detectable IBDV antigen in these tissues. IBDV-IM induced systemic circulating nitrite levels in over 86% of the birds at days 2 and 3 PI. IBDV-IM suppressed most vigorously the splenic mitogenic response on days 3-8 PI. Among the three vaccine strains, IBDV-B2 was the most virulent of the three, inducing a significant suppression of the mitogenic response (P < 0.05) and the most vigorous lesions in the bursa of Fabricius with the highest possible lesion score of 4 at 3 days PI (P < 0.05). IBDV-BVM was the mildest strain, not inducing any detectable lesions in lymphoid tissue at the tested time points. Whereas all IBDV-BVM-inoculated and 67% and 33% of the IBDV-Lukert- and IBDV-B2-inoculated birds, respectively, had detectable IBDV antigen in the bursa at 4 days postchallenge, none of the IBDV-IM-inoculated birds was positive for IBDV by immunohistochemistry. IBDV-IM induced the highest enzyme-linked immunosorbent assay (ELISA) antibody levels detected at days 8-29 PI (P < 0.05) and the best protection against challenge virus replication in comparison with IBDV-B2 and IBDV-Lukert. Only one of five IBDV-BVM-inoculated birds developed anti-IBDV ELISA antibodies at 29 days PI, and none of the birds was protected against IBDV challenge. We speculate that better protection with more virulent strains was due to more systemic antigenic stimulation on the basis of higher replication of IBDV in extrabursal lymphoid tissues. Interestingly, IBDV-IM did not differ from IBDV-B2 and IBDV-Lukert in its ability to induce T cell accumulation in the bursa at 8 days PI and local interferon-gamma induction from days 2 to 5 PI. These results suggested that the local T cell events in the bursa alone may not be indicative of a rapid and protective immune response.

Animals↗

Protective immunity against infectious bursal disease virus in chickens in the absence of virus-specific antibodies.

The role of cell-mediated immunity (CMI) in pathogenesis of infectious bursal disease virus (IBDV) was investigated. One-day-old specific pathogen-free chickens were treated with 3mg of cyclophosphamide (Cy) per chicken for 4 consecutive days and, 3 weeks later, infected with the IBDV-IM strain. Chickens were examined for: (a) mitogenic response of splenocytes to ConA, as an indicator of T-cell functions in vitro, (b) antibody against IBDV by ELISA, (c) IBDV genome in various tissues by RT-PCR and (d) immunological memory. At the time of IBDV infection, Cy-treated chickens had depleted bursal tissue (an avian primary B-cell lymphoid organ), severely compromised antibody-producing ability, but normal T-cell response to ConA. In primary infection, no detectable antibody against IBDV antigen in Cy-treated, IBDV-infected chickens was observed up to 28 days post-infection (PI), while IBDV genome was detected by RT-PCR in spleen, thymus, liver and blood until 10 days PI. Like intact control chickens infected with IBDV, Cy-treated, IBDV-infected chickens suppressed splenocytes responses to ConA from 5 to 10 days PI, suggesting that intact control as well as Cy-treated chickens responded similarly to IBDV infection in the early phase. Following re-infection with IBDV, no detectable secondary antibody response to IBDV as well as IBDV genome in tissues were observed in Cy-treated chickens, while intact control chickens developed vigorous secondary antibody response. Similar to intact control chickens infected with IBDV, Cy-treated chickens after second infection with IBDV did not suppress splenocyte response to ConA. These results suggested that in the absence of detectable anti-IBDV antibodies, protection of Cy-treated chickens from IBDV infection may occur via immunological memory mediated by CMI. We concluded that under normal conditions, IBDV induces a protective antibody response, however, in the absence of antibody, CMI alone is adequate in protecting birds against virulent IBDV.

Animals↗

Antibody titers to infectious bursal disease virus in broiler chicks after vaccination at one day of age with infectious bursal disease virus and Marek's disease virus.

The effect of day-of-age vaccination with infectious bursal disease virus (IBDV) alone or in combination with Marek's disease virus (MDV) in broiler chicks was investigated. One-day-old commercial broiler progeny obtained from IBDV-immunized breeder flocks were vaccinated subcutaneously according to the manufacturer's directions with live-attenuated commercially available vaccines as follows: IBDV alone, MDV alone, IBDV + MDV, and unvaccinated control. IBDV was not detected after vaccination by reverse transcriptase/polymerase chain reaction in any of the bursal, thymic, and splenic tissues tested. Serum IBDV antibody levels, as monitored by enzyme-linked immunosorbent assay (ELISA), showed similar rates of decline among the four groups, and, by day 28 postinoculation, serum antibody levels in all groups were below detectable limits. IBDV-specific neutralizing maternal antibody (MA) titers in the IBDV + MDV and control groups, as monitored by the virus neutralization assay (VN), remained higher and declined more slowly throughout the experiment as compared with VN titers in the IBDV- and the MDV-vaccinated groups. In a second experiment, groups of one-day-old broiler chicks were vaccinated as in Experiment 1. Serum IBDV antibody detected by ELISA and VN assay declined parallel to those observed in Experiment 1. Histopathologic lesions characteristic of IBDV were not observed in any of the groups. Vaccination with MDV alone was associated with increased rates of IBDV neutralizing MA decline similar to those caused by vaccination with IBDV alone, whereas concurrent vaccination with IBDV + MDV was not associated with increased rates of IBDV neutralizing MA decline over that of nonvaccinated controls. Results of these studies indicate that IBDV vaccination at 1 day of age does not cause accelerated IBDV-specific MA decline as detected by ELISA but does appear to cause an accelerated decline in neutralizing IBDV-specific MA. Furthermore, vaccination with IBDV at 1 day of age appeared to slow the accelerated rate of IBDV neutralizing antibody decline caused by MDV vaccination.

Animals↗

In-situ apoptosis in chickens infected with infectious bursal disease virus.

Groups of specific pathogen-free chickens aged 3 weeks were inoculated with one of three strains of infectious bursal disease virus (IBDV), namely: (1) a classical virulent strain, IM-IBDV; (2) an antigenic variant-E strain, VE-IBDV; and (3) an attenuated vaccine strain, B2-IBDV. The bursa of Fabricius and thymus were examined 1 to 5 days after inoculation for histopathological lesions, IBDV antigen, and in-situ apoptosis. Infection of chickens with IM-, VE-, or B2-IBDV resulted in the appearance of large numbers of apoptotic bursal lymphocytes, both in IBDV antigen-positive and antigen-negative bursal follicles. B2-IBDV induced a slower increase in the IBDV antigen-positive cells and apoptotic cells than did IM- and VE-IBDV. The results suggested that virulent strains and vaccine strains of IBDV enhance endogenous apoptosis of bursal lymphocytes that are free of detectable IBDV antigen. Infection of chickens with IM-IBDV, but not with VE- or B2-IBDV, caused a significant increase in apoptotic cells in the thymic cortical lymphocytes. The apoptotic lymphocytes in the thymus were negative for IBDV antigen. This result indicated that histopathological lesions in the thymus of IM-IBDV-infected chickens may be due to enhanced endogenous apoptosis of thymic lymphocytes without IBDV antigen production in the cells.

Animals↗